Skip to main content
SpringerLink
Log in

Insulin degludec/liraglutide cost effective in Slovakia

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 2015 euros

Reference

  • Psota M, et al. Cost-effectiveness analysis of IDegLira versus basal-bolus insulin for patients with type 2 diabetes in the Slovak health system. ClinicoEconomics and Outcomes Research 2017: 749-762, No. 9, 12 Dec 2017. Available from: URL: https://doi.org/10.2147/CEOR.S143127

    Article  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Insulin degludec/liraglutide cost effective in Slovakia. PharmacoEcon Outcomes News 794, 17 (2018). https://doi.org/10.1007/s40274-018-4615-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-018-4615-x

Search

Navigation